SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:liu-157266"
 

Sökning: onr:"swepub:oai:DiVA.org:liu-157266" > Vedolizumab in Refr...

  • Riviere, PaulineKatholieke Univ Leuven, Belgium (författare)

Vedolizumab in Refractory Microscopic Colitis : An International Case Series

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2018-10-17
  • Oxford University Press,2019
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-157266
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-157266URI
  • https://doi.org/10.1093/ecco-jcc/jjy169DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background Evidence for second-line therapy in patients with microscopic colitis [MC] failing budesonide is scarce, although anti-tumour necrosis factors [anti-TNFs], methotrexate and azathioprine have been reported to be effective in small cohort studies. Vedolizumab, a monoclonal antibody targeting 47-integrin, prevents homing of T-cells to the gut. We evaluated clinical remission with vedolizumab in budesonide-refractory MC patients. Methods We solicited gastroenterologists in Europe and Canada for cases of MC treated with vedolizumab. Vedolizumab 300 mg IV was administered at weeks 0, 2 and 6, and then every 8 weeks. Clinical remission and histological remission were defined as less than three stools per day and normalization of histology, respectively, after induction treatment. Results Eleven cases were retrieved (nine females, lymphocytic colitis [LC] n = 5, collagenous colitis [CC] n = 6). Median [interquartile range] disease duration at vedolizumab initiation was 51 [29-70] months. Nine of 11 patients had failed one immunosuppressant and ten of 11 at least one anti-TNF agent. After three infusions of vedolizumab, clinical remission was observed in 5/11 patients [two LC and three CC] of whom three remained well with maintenance therapy [median duration of 13 months]. Biopsies were obtained from 9/11 patients. Histological remission was observed in 3/4 patients with clinical remission [2/3 CC, 1/1 LC] and 0/5 patients without clinical improvement. Conclusion In a series of highly refractory MC patients, vedolizumab induced clinical remission in 5/11 subjects, of whom 75% showed normalized histology. Larger randomized trials are needed to assess the efficacy of vedolizumab in patients with MC.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Münch, Andreas,1970-Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Magtarmmedicinska kliniken(Swepub:liu)andsa76 (författare)
  • Michetti, PierreGastroenterol La Source Beaulieu, Switzerland (författare)
  • Chande, NileshWestern Univ, Canada (författare)
  • de Hertogh, GertKatholieke Univ Leuven, Belgium (författare)
  • Schoeters, PatrickAZA Herentals, Belgium (författare)
  • Ferrante, MarcKatholieke Univ Leuven, Belgium (författare)
  • Vermeire, SeverineKatholieke Univ Leuven, Belgium (författare)
  • Van Assche, GertKatholieke Univ Leuven, Belgium (författare)
  • Katholieke Univ Leuven, BelgiumAvdelningen för neuro- och inflammationsvetenskap (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Crohn's & Colitis: Oxford University Press13:3, s. 337-3401873-99461876-4479

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy